secwatch.observer — SEC 8-K summary
======================================

Issuer:     Marker Therapeutics, Inc. (MRKR)
CIK:        0001094038
Form:       8-K
Filed at:   2023-07-10T23:59:59+00:00
Accession:  0001104659-23-079310
Event type: regulatory
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Marker Therapeutics' MT-401 receives EMA Orphan Drug Designation for AML
------------------------------------------------------------------------

- EMA granted Orphan Drug Designation for zedenoleucel (MT-401) for acute myeloid leukemia (AML).
- MT-401 is a non-genetically modified multiTAA-specific T cell therapy targeting four AML-associated antigens.
- Phase 2 trial ongoing for relapsed AML after allogeneic HSCT; FDA also granted orphan designation in 2020.
- Benefits include 10-year EU market exclusivity post-approval, reduced regulatory fees, and scientific advice.
- Relapsed AML after HSCT has median survival <1 year, underscoring the need for new therapies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1094038/000110465923079310/0001104659-23-079310-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1094038/000110465923079310/tm2320895d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-079310

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer